As per the report titled ‘North America Bioreactors Market Size By Technology, Molecule, End-use, Cell, Industry Analysis Report, Country Outlook, Application Potential, Competitive Market Share & Forecast, 2019 - 2025’, available with Market Study Report, North America bioreactors market is estimated to surpass USD 790 million by the year 2025.  
 

Ongoing development of orphan drugs to provide effective healthcare solutions, in tandem with improving diagnostics, treatments, and monitoring services for chronic diseases are fueling the growth of North America bioreactors market. Shifting preference for personalized medicines and increasing FDA approvals for orphan drugs will further augment the market growth during the forecast period.
 

Rising prevalence of chronic disorders and inflowing investments in biopharmaceutical industry are positively impacting the market outlook. Surging demand for effective vaccines and favorable government initiatives towards healthcare infrastructure development, coupled with innovations in reactor tanks are stimulating the expansion of North America bioreactors industry.
 

However, regulatory norms pertaining to single-use bioreactor, vulnerability to leaching, and low storage capacity may hinder the market growth during the forecast period. Furthermore, disposal of massive amounts of plastic derivatives is a significant threat to the environment, and hence is negatively impacting the bioreactors market in North America.
 

Based on the cell type, mammalian cells segment is anticipated to grow with a CAGR of 17.9% during 2019-2025, on account of its widespread application in the production of therapeutic proteins and viral vaccines. Advancement of gene therapy and tissue engineering coupled with growing demand for smart and regenerative medications will boost the market growth.
 

In terms of molecule, monoclonal antibodies (mAb) segment amassed USD 100 million in 2018 and is anticipated to grow considerably during the study period. The growth is attributable to the use of these antibodies for the treatment of various diseases such as breast cancers, rheumatoid arthritis, asthma, leukemia, and transplant rejection. Availability of bioreactors meeting the specifications for mAb production will favor the product adoption.
 

Elaborating on the technology scope, wave-induced motion SUB segment of North America bioreactors market is estimated to expand with a 17.3% CAGR through 2025, on account of extensive use of this technology in modern biotechnological processes. These reactors are generally used in pilot plant scale-up as they offer flexibility with optimum productivity.
 

Speaking of the end-use spectrum, North America bioreactors industry from R&D segment was worth USD 127.9 million in 2018 and is expected to show a positive growth trend during the analysis period.  Emergence of new facilities to meet the production demand, in consort with numerous pipeline drugs are supporting the segment growth.
 

Request sample copy of this Report@ https://www.marketstudyreport.com/request-a-sample/2506075/
 

Considering the geographical landscape, Canada bioreactors market is projected to record 17.9% CAGR during 2019-2025. Dense presence of major market players, growing adoption of single-use bioreactors, and ongoing R&D for disposable bioreactors are the major factors supporting the regional market growth.
 

The prominent players of North America bioreactors market are PBS Biotech, Thermo Fisher Scientific, GE Healthcare, Cellexus Ltd., Merck Group, Applikon Biotechnology, Inc., and Sartorius Stedim Biotech Group.